![](https://endpts.com/wp-content/uploads/2022/08/Benjamin-Oakes-Scribe-Therapeutics-CEO.jpg)
Benjamin Oakes, Scribe Therapeutics CEO
Lilly’s Prevail taps Jennifer Doudna's spinout Scribe Therapeutics for neuro genetic medicines
Scribe Therapeutics found another partner, this time with Prevail Therapeutics, a subsidiary of Eli Lilly, in a $75 million upfront deal for neuromuscular and neurological …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.